STOCK TITAN

[Form 4] MiMedx Group, Inc Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

MiMedx Group director James L. Bierman acquired 28,609 shares of common stock on June 18, 2025 at a price of $6.47 per share, bringing his total direct holdings to 212,771 shares.

The acquisition represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3. The awarded shares will vest upon the earlier of:

  • 12 months from grant date
  • The next annual meeting of shareholders

The Form 4 filing was signed by William F. Hulse as attorney-in-fact for Bierman on June 23, 2025. This transaction demonstrates continued alignment of director interests with shareholders through equity-based compensation.

Il direttore di MiMedx Group, James L. Bierman, ha acquisito 28.609 azioni ordinarie il 18 giugno 2025 al prezzo di 6,47 $ per azione, portando il totale delle sue partecipazioni dirette a 212.771 azioni.

L'acquisizione rappresenta una concessione annuale di azioni vincolate ai direttori non dipendenti ed è esente ai sensi della Regola 16b-3. Le azioni assegnate matureranno al primo verificarsi di:

  • 12 mesi dalla data di assegnazione
  • La prossima assemblea annuale degli azionisti

Il modulo 4 è stato firmato da William F. Hulse in qualità di procuratore per Bierman il 23 giugno 2025. Questa operazione dimostra un continuo allineamento degli interessi dei direttori con quelli degli azionisti attraverso una remunerazione basata su azioni.

El director de MiMedx Group, James L. Bierman, adquirió 28,609 acciones comunes el 18 de junio de 2025 a un precio de $6.47 por acción, aumentando su participación directa total a 212,771 acciones.

La adquisición representa una concesión anual de acciones restringidas para directores no empleados y está exenta bajo la Regla 16b-3. Las acciones otorgadas se consolidarán al primero de los siguientes eventos:

  • 12 meses desde la fecha de concesión
  • La próxima junta anual de accionistas

El formulario 4 fue firmado por William F. Hulse como apoderado de Bierman el 23 de junio de 2025. Esta transacción demuestra una continua alineación de los intereses de los directores con los accionistas mediante la compensación basada en acciones.

MiMedx 그룹 이사 James L. Bierman2025년 6월 18일에 보통주 28,609주를 주당 $6.47에 취득하여 총 직접 보유 주식 수를 212,771주로 늘렸습니다.

이번 취득은 비임원 이사들에게 연례로 부여되는 제한 주식 보너스에 해당하며, 규칙 16b-3에 따라 면제됩니다. 부여된 주식은 다음 중 빠른 시점에 베스팅됩니다:

  • 부여일로부터 12개월 경과 시
  • 다음 연례 주주총회 시

폼 4 제출 서류는 2025년 6월 23일 William F. Hulse가 Bierman의 대리인 자격으로 서명했습니다. 이 거래는 주식 기반 보상을 통해 이사와 주주 간 이해관계의 지속적인 일치를 보여줍니다.

Le directeur du groupe MiMedx, James L. Bierman, a acquis 28 609 actions ordinaires le 18 juin 2025 au prix de 6,47 $ par action, portant son total de participations directes à 212 771 actions.

Cette acquisition représente une attribution annuelle d'actions restreintes aux administrateurs non salariés et est exemptée en vertu de la règle 16b-3. Les actions attribuées seront acquises à la première échéance de :

  • 12 mois à compter de la date d'attribution
  • La prochaine assemblée générale annuelle des actionnaires

Le dépôt du formulaire 4 a été signé par William F. Hulse en tant que mandataire de Bierman le 23 juin 2025. Cette opération illustre l'alignement continu des intérêts des administrateurs avec ceux des actionnaires par le biais d'une rémunération en actions.

Der Direktor der MiMedx Group, James L. Bierman, erwarb am 18. Juni 2025 28.609 Stammaktien zu einem Preis von 6,47 $ pro Aktie und erhöhte damit seinen direkten Gesamtbestand auf 212.771 Aktien.

Der Erwerb stellt eine jährliche Zuteilung von eingeschränkten Aktien an nicht angestellte Direktoren dar und ist gemäß Regel 16b-3 ausgenommen. Die zugewiesenen Aktien werden zum früheren Zeitpunkt von:

  • 12 Monate ab dem Zuteilungsdatum
  • Der nächsten jährlichen Hauptversammlung der Aktionäre

Das Formular 4 wurde am 23. Juni 2025 von William F. Hulse als Bevollmächtigter für Bierman unterzeichnet. Diese Transaktion zeigt die fortgesetzte Übereinstimmung der Interessen der Direktoren mit denen der Aktionäre durch aktienbasierte Vergütung.

Positive
  • None.
Negative
  • None.

Il direttore di MiMedx Group, James L. Bierman, ha acquisito 28.609 azioni ordinarie il 18 giugno 2025 al prezzo di 6,47 $ per azione, portando il totale delle sue partecipazioni dirette a 212.771 azioni.

L'acquisizione rappresenta una concessione annuale di azioni vincolate ai direttori non dipendenti ed è esente ai sensi della Regola 16b-3. Le azioni assegnate matureranno al primo verificarsi di:

  • 12 mesi dalla data di assegnazione
  • La prossima assemblea annuale degli azionisti

Il modulo 4 è stato firmato da William F. Hulse in qualità di procuratore per Bierman il 23 giugno 2025. Questa operazione dimostra un continuo allineamento degli interessi dei direttori con quelli degli azionisti attraverso una remunerazione basata su azioni.

El director de MiMedx Group, James L. Bierman, adquirió 28,609 acciones comunes el 18 de junio de 2025 a un precio de $6.47 por acción, aumentando su participación directa total a 212,771 acciones.

La adquisición representa una concesión anual de acciones restringidas para directores no empleados y está exenta bajo la Regla 16b-3. Las acciones otorgadas se consolidarán al primero de los siguientes eventos:

  • 12 meses desde la fecha de concesión
  • La próxima junta anual de accionistas

El formulario 4 fue firmado por William F. Hulse como apoderado de Bierman el 23 de junio de 2025. Esta transacción demuestra una continua alineación de los intereses de los directores con los accionistas mediante la compensación basada en acciones.

MiMedx 그룹 이사 James L. Bierman2025년 6월 18일에 보통주 28,609주를 주당 $6.47에 취득하여 총 직접 보유 주식 수를 212,771주로 늘렸습니다.

이번 취득은 비임원 이사들에게 연례로 부여되는 제한 주식 보너스에 해당하며, 규칙 16b-3에 따라 면제됩니다. 부여된 주식은 다음 중 빠른 시점에 베스팅됩니다:

  • 부여일로부터 12개월 경과 시
  • 다음 연례 주주총회 시

폼 4 제출 서류는 2025년 6월 23일 William F. Hulse가 Bierman의 대리인 자격으로 서명했습니다. 이 거래는 주식 기반 보상을 통해 이사와 주주 간 이해관계의 지속적인 일치를 보여줍니다.

Le directeur du groupe MiMedx, James L. Bierman, a acquis 28 609 actions ordinaires le 18 juin 2025 au prix de 6,47 $ par action, portant son total de participations directes à 212 771 actions.

Cette acquisition représente une attribution annuelle d'actions restreintes aux administrateurs non salariés et est exemptée en vertu de la règle 16b-3. Les actions attribuées seront acquises à la première échéance de :

  • 12 mois à compter de la date d'attribution
  • La prochaine assemblée générale annuelle des actionnaires

Le dépôt du formulaire 4 a été signé par William F. Hulse en tant que mandataire de Bierman le 23 juin 2025. Cette opération illustre l'alignement continu des intérêts des administrateurs avec ceux des actionnaires par le biais d'une rémunération en actions.

Der Direktor der MiMedx Group, James L. Bierman, erwarb am 18. Juni 2025 28.609 Stammaktien zu einem Preis von 6,47 $ pro Aktie und erhöhte damit seinen direkten Gesamtbestand auf 212.771 Aktien.

Der Erwerb stellt eine jährliche Zuteilung von eingeschränkten Aktien an nicht angestellte Direktoren dar und ist gemäß Regel 16b-3 ausgenommen. Die zugewiesenen Aktien werden zum früheren Zeitpunkt von:

  • 12 Monate ab dem Zuteilungsdatum
  • Der nächsten jährlichen Hauptversammlung der Aktionäre

Das Formular 4 wurde am 23. Juni 2025 von William F. Hulse als Bevollmächtigter für Bierman unterzeichnet. Diese Transaktion zeigt die fortgesetzte Übereinstimmung der Interessen der Direktoren mit denen der Aktionäre durch aktienbasierte Vergütung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BIERMAN JAMES L

(Last) (First) (Middle)
1775 WEST OAK COMMONS COURT

(Street)
MARIETTA GA 30062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 28,609(1) A $6.47 212,771 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders
Remarks:
/s/ William F. Hulse as attorney in fact for James L. Bierman 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MDXG shares did Director James Bierman acquire on June 18, 2025?

Director James Bierman acquired 28,609 shares of MDXG common stock on June 18, 2025, as part of an annual restricted stock grant to non-employee directors at a price of $6.47 per share.

What is the vesting period for MDXG's director stock grants in 2025?

The restricted stock grant for MDXG's non-employee directors vests upon the earlier of 12 months or the next annual meeting of shareholders. This grant was made under Rule 16b-3 exemption.

How many MDXG shares does James Bierman own after the June 2025 stock grant?

Following the restricted stock grant transaction, James Bierman beneficially owns 212,771 shares of MDXG common stock directly (Form: Direct Ownership).

Did MDXG Director James Bierman purchase or receive these shares as compensation?

The shares were received as compensation, specifically as an annual restricted stock grant to non-employee directors. The Form 4 indicates this was a grant exempt under Rule 16b-3, which typically applies to equity compensation awards.
Mimedx Group Inc

NASDAQ:MDXG

MDXG Rankings

MDXG Latest News

MDXG Latest SEC Filings

MDXG Stock Data

877.35M
144.97M
2.72%
69.9%
2.78%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States
MARIETTA